Tower Research Capital LLC (Trc) Processa Pharmaceuticals, Inc. Transaction History

Tower Research Capital LLC (Trc)

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.18 - $0.84 $1,601 - $7,475	-8,899 Reduced 88.16%	1,195 $0
Q3 2023 Nov 14, 2023	BUY	$0.24 - $0.53 $311 - $687	1,298 Added 14.76%	10,094 $2,000
Q2 2023 Aug 14, 2023	SELL	$0.44 - $0.73 $52 - $87	-120 Reduced 1.35%	8,796 $4,000
Q1 2023 May 09, 2023	BUY	$0.41 - $1.3 $286 - $908	699 Added 8.51%	8,916 $4,000
Q4 2022 Feb 10, 2023	BUY	$1.1 - $50.0 $4,016 - $182,550	3,651 Added 79.96%	8,217 $9,000
Q3 2022 Nov 10, 2022	BUY	$2.0 - $46.8 $6,274 - $146,811	3,137 Added 219.52%	4,566 $10,000
Q2 2022 Aug 15, 2022	SELL	$1.68 - $3.55 $2,864 - $6,052	-1,705 Reduced 54.4%	1,429 $4,000
Q1 2022 May 12, 2022	BUY	$3.01 - $5.21 $4,578 - $7,924	1,521 Added 94.3%	3,134 $9,000
Q4 2021 Feb 14, 2022	BUY	$4.03 - $8.42 $6,500 - $13,581	1,613 New	1,613 $8,000
Q2 2021 Aug 16, 2021	SELL	$6.15 - $10.95 $1,445 - $2,573	-235 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$5.96 - $13.15 $6,609 - $14,583	-1,109 Reduced 82.51%	235 $3,000
Q4 2020 Feb 16, 2021	BUY	$3.95 - $8.48 $5,308 - $11,397	1,344 New	1,344 $9,000

Ticker PCSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,856,200
Market Cap $14.3M
Description
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosi...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.